Stock CORNERSTONE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cornerstone Therapeutics, Inc.

Equities

US21924P1030

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cornerstone Therapeutics, Inc.

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Inc. Stockholders Approve Merger
PU
Cornerstone Therapeutics Inc. Stockholders Approve Merger
MW
Cornerstone Therapeutics Adjourns Special Meeting of Stockholders
MW
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call
PU
Cornerstone Therapeutics, Inc. : Shareholder Rights Law Firm Johnson & Weaver, LLP, is Investigating the Cornerstone Buyout
BU
Cornerstone Therapeutics, Inc. : Law Firm Brower Piven Announces Investigation of Cornerstone Therapeutics, Inc. Proposed Acquisition
BU
Cornerstone Therapeutics, Inc. : Finkelstein Thompson LLP Announces Investigation of Cornerstone Therapeutics Inc. Buyout
BU
Cornerstone Therapeutics, Inc. : Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement for a Merger Transaction in Which Chiesi Will Acquire 100 Percent Ownership of Cornerstone for $9.50 per Share in Cash
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Reports First Quarter 2013 Financial Results
PU
Cornerstone Therapeutics, Inc. : REMINDER: Cornerstone Therapeutics to Host First Quarter 2013 Conference Call
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Sues to Enforce Its CARDENE(R) I.V. Patents
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2012 Conference Call
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Receives CARDENE(R) I.V. (Nicardipine Hydrochloride) Paragraph IV Notice Letter
PU
Cornerstone Therapeutics, Inc. : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cornerstone Therapeutics Inc. Shareholders
BU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Acquire EKR Therapeutics, Accelerating Expansion in Hospital Market
PU
Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
PU
CORNERSTONE THERAP : New Research Indicates Treating Neonatal Respiratory Distress Syndrome with CUROSURF® Results in Lower Rate of Mortality Compared to Competitive Surfactants
BU
CORNERSTONE THERAP : Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
PR
CORNERSTONE THERAP : Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Cornerstone Therapeutics, Inc.